Author

Klaas Nico Faber

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Klaas Nico Faber  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Klaas Nico Faber  et al.

STUDYING THE MUTUAL INTERACTION BETWEEN THE HUMAN GUT EPITHELIUM AND THE PREDOMINANTLY ANAEROBIC GUT MICROBIOME IN HOXBAN-STOOL
STUDYING THE MUTUAL INTERACTION BETWEEN THE HUMAN GUT EPITHELIUM AND THE PREDOMINANTLY ANAEROBIC GUT MICROBIOME IN HOXBAN-STOOL

Klaas Nico Faber  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Klaas Nico Faber  et al.

THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL
THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL

Klaas Nico Faber  et al.

FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18
FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18

Klaas Nico Faber  et al.

SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE
SYSTEMIC IRON DEFICIENCY AND INTESTINAL INFLAMMATION CONTROL GUT MUCOSAL HIF-1? AND TFRC ACTIVATION IN INFLAMMATORY BOWEL DISEASE

Klaas Nico Faber  et al.

ANTI-INFLAMMATORY ACTIONS OF BUTYRATE ON MACROPHAGES AND EPITHELIAL CELLS IN INTESTINAL MUCOSA OF INFLAMMATORY BOWEL DISEASE PATIENTS
ANTI-INFLAMMATORY ACTIONS OF BUTYRATE ON MACROPHAGES AND EPITHELIAL CELLS IN INTESTINAL MUCOSA OF INFLAMMATORY BOWEL DISEASE PATIENTS

Klaas Nico Faber  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Klaas Nico Faber  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Klaas Nico Faber  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Klaas Nico Faber  et al.

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Klaas Nico Faber  et al.

INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE
INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE

Klaas Nico Faber  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Klaas Nico Faber  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Klaas Nico Faber  et al.

IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING
IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING

Klaas Nico Faber  et al.

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Klaas Nico Faber  et al.

Item 1 - 17 / 17
1